Clinical trial
Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
NCT00162097 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00162097 |
|---|---|
| Title | Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment |
| Official title | Pharmacokinetics of Efavirenz During Treatment of HIV-1 Infected Subjects With Hepatic Impairment. |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections, Hepatic Impairment |
| Intervention type | Drug |
| Interventions | efavirenz containing antiretroviral regimen |
| Enrollment | 21 |
| Start date | Nov 1, 2004 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Sep 13, 2005 |
| Last update posted | Sep 14, 2010 |
| Countries | Italy, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: